112 related articles for article (PubMed ID: 27236805)
1. Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2.
Idorn M; Thor Straten P; Svane IM; Met Ö
Methods Mol Biol; 2016; 1428():261-76. PubMed ID: 27236805
[TBL] [Abstract][Full Text] [Related]
2. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
3. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.
Kershaw MH; Wang G; Westwood JA; Pachynski RK; Tiffany HL; Marincola FM; Wang E; Young HA; Murphy PM; Hwu P
Hum Gene Ther; 2002 Nov; 13(16):1971-80. PubMed ID: 12427307
[TBL] [Abstract][Full Text] [Related]
4. Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.
Pato A; Eisenberg G; Machlenkin A; Margalit A; Cafri G; Frankenburg S; Merims S; Peretz T; Lotem M; Gross G
Clin Exp Immunol; 2015 Nov; 182(2):220-9. PubMed ID: 26212048
[TBL] [Abstract][Full Text] [Related]
5. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy.
Sapoznik S; Ortenberg R; Galore-Haskel G; Kozlovski S; Levy D; Avivi C; Barshack I; Cohen CJ; Besser MJ; Schachter J; Markel G
Cancer Immunol Immunother; 2012 Oct; 61(10):1833-47. PubMed ID: 22441657
[TBL] [Abstract][Full Text] [Related]
6. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Zikich D; Schachter J; Besser MJ
Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
[TBL] [Abstract][Full Text] [Related]
7. Selective modification of antigen-specific T cells by RNA electroporation.
Mitchell DA; Karikari I; Cui X; Xie W; Schmittling R; Sampson JH
Hum Gene Ther; 2008 May; 19(5):511-21. PubMed ID: 18471037
[TBL] [Abstract][Full Text] [Related]
8. Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man.
Kasid A; Morecki S; Aebersold P; Cornetta K; Culver K; Freeman S; Director E; Lotze MT; Blaese RM; Anderson WF
Proc Natl Acad Sci U S A; 1990 Jan; 87(1):473-7. PubMed ID: 2404283
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.
Mazzarella T; Cambiaghi V; Rizzo N; Pilla L; Parolini D; Orsenigo E; Colucci A; Modorati G; Doglioni C; Parmiani G; Maccalli C
Cancer Immunol Immunother; 2012 Aug; 61(8):1169-82. PubMed ID: 22207316
[TBL] [Abstract][Full Text] [Related]
10. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
[TBL] [Abstract][Full Text] [Related]
11. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.
Zhou J; Shen X; Huang J; Hodes RJ; Rosenberg SA; Robbins PF
J Immunol; 2005 Nov; 175(10):7046-52. PubMed ID: 16272366
[TBL] [Abstract][Full Text] [Related]
12. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
[TBL] [Abstract][Full Text] [Related]
13. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.
Donia M; Junker N; Ellebaek E; Andersen MH; Straten PT; Svane IM
Scand J Immunol; 2012 Feb; 75(2):157-67. PubMed ID: 21955245
[TBL] [Abstract][Full Text] [Related]
14. Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40.
Levin N; Weinstein-Marom H; Pato A; Itzhaki O; Besser MJ; Eisenberg G; Peretz T; Lotem M; Gross G
J Immunol; 2018 Nov; 201(10):2959-2968. PubMed ID: 30305327
[TBL] [Abstract][Full Text] [Related]
15. IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma.
Melief SM; Visser M; van der Burg SH; Verdegaal EME
Cancer Immunol Immunother; 2017 Jul; 66(7):913-926. PubMed ID: 28401257
[TBL] [Abstract][Full Text] [Related]
16. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory cell infiltrates in advanced metastatic uveal melanoma.
Krishna Y; McCarthy C; Kalirai H; Coupland SE
Hum Pathol; 2017 Aug; 66():159-166. PubMed ID: 28655639
[TBL] [Abstract][Full Text] [Related]
18. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.
Kremer V; Ligtenberg MA; Zendehdel R; Seitz C; Duivenvoorden A; Wennerberg E; Colón E; Scherman-Plogell AH; Lundqvist A
J Immunother Cancer; 2017 Sep; 5(1):73. PubMed ID: 28923105
[TBL] [Abstract][Full Text] [Related]
19. Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells.
Weinstein-Marom H; Levin N; Pato A; Shmuel N; Sharabi-Nov A; Peretz T; Eisenberg G; Lotem M; Itzhaki O; Besser MJ; Gross G
J Immunother; 2019; 42(2):43-50. PubMed ID: 30489430
[TBL] [Abstract][Full Text] [Related]
20. Adoptive T-cell transfer in melanoma.
Itzhaki O; Levy D; Zikich D; Treves AJ; Markel G; Schachter J; Besser MJ
Immunotherapy; 2013 Jan; 5(1):79-90. PubMed ID: 23256800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
